Posts by: Forest Ray

Forest Ray

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

December 9, 2020December 9, 2020

UniQure Shares Long-term Data About AMT-061 and AMT-060 Gene Therapy Candidates

News

Two potential gene therapies — AMT-060 and AMT-061 (etranacogene dezaparvovec) — lead to safe and long-term increases in factor IX (FIX) activity, as well as fewer bleeds among patients ... Read more

December 7, 2020December 7, 2020

MarzAA on FDA Fast Track to Treat Hemophilia A or B With Inhibitors

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to marzeptacog alfa activated (MarzAA), a lab-made version of clotting factor VIIa for the subcutaneous (under-the-skin) treatment ... Read more

October 28, 2020October 28, 2020

Patients Report Mostly High Satisfaction With US Hemophilia Treatment Centers

News

People living with bleeding disorders such as hemophilia and von Willebrand disease report consistently high levels of satisfaction with the care they receive at U.S. hemophilia treatment centers (HTCs), ... Read more

October 19, 2020October 26, 2020

Hemlibra ‘Comparable or Better’ Treatment for Hemophilia A, ICER Finds

News

At standard U.S. doses, Hemlibra (emicizumab) provides comparable or even superior clinical benefits than prophylactic factor VIII (FVIII) replacement therapy among adults with severe hemophilia A and no inhibitors, according ... Read more

October 16, 2020October 16, 2020

Alprolix Shows Key Benefits for Hemophilia B Patients in Real-World Setting

News

Treatment with Alprolix improves bleeding control, reduces the need for infusions, and improves patient compliance among people with hemophilia B, according to a review of real-world data. The study, “Real‐world ... Read more

October 12, 2020October 13, 2020

NIH Awards $1.5M for Finger Blood Test of FVIII, Hemlibra Levels

News

The National Institutes of Health (NIH) awarded the DNA Medicine Institute (DMI) a $1.5 million grant to advance a quick and easy way of monitoring factor VIII (FVIII) and Hemlibra (emicizumab) blood levels in people with hemophilia A, ... Read more

October 7, 2020October 7, 2020

Virtual ‘Unite for Bleeding Disorders Walk’ Set for Oct. 10 in US

News

The National Hemophilia Foundation (NHF) is inviting the country’s bleeding disorder community and others to participate in a first virtual Unite for Bleeding Disorders Walk on Oct. 10. The ... Read more

October 5, 2020October 5, 2020

Recall on Ferring’s Intranasal Desmopressin Therapies to Affect Availability Into 2021

News

A recall on Ferring Pharmaceuticals‘ intranasal desmopressin compounds — used to treat mild to moderate hemophilia A and von Willebrand disease type 1 — is expected to affect the ... Read more

September 11, 2020September 11, 2020

EMA Also Pushes Back Decision on Roctavian as Hemophilia A Gene Therapy

News

The European Medicines Agency (EMA) is asking for a full year’s worth of data from a Phase 3 trial of Roctavian as it considers approving this potential gene therapy for ... Read more

September 9, 2020September 9, 2020

Carton Label Mix-Up Causes Nationwide Recall of Tranexamic Acid Injection

News

The global pharmaceutical company Mylan has voluntarily issued a nationwide recall of four lots of tranexamic acid injection — a generic form of Cyklokapron — and of amiodarone HCl ... Read more